Valuation: IRLAB Therapeutics AB

Market Cap 289M 29.07M 25.99M 24.05M 21.77M 40.75M 2.77B 41.42M 114M 1.45B 109M 107M 4.58B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 289M 29.07M 25.99M 24.05M 21.77M 40.75M 2.77B 41.42M 114M 1.45B 109M 107M 4.58B EV / Sales 2026 *
2.86x
EV / Sales 2027 * 2.02x
Free-Float
83.4%
Yield 2026 *
-
Yield 2027 * -
1 day+2.26%
1 week-3.63%
Current month+8.98%
1 month+5.51%
3 months+59.71%
6 months+29.39%
Current year+1.02%
1 week 1.86
Extreme 1.858
2.09
1 month 1.7
Extreme 1.7
2.09
Current year 1.17
Extreme 1.17
2.14
1 year 1.17
Extreme 1.17
2.78
3 years 1.17
Extreme 1.17
20.2
5 years 1.17
Extreme 1.17
51.5
10 years 1.17
Extreme 1.17
110
Manager TitleAgeSince
Chief Executive Officer 63 01/08/2024
Corporate Officer/Principal 60 01/01/2013
Chief Tech/Sci/R&D Officer 65 01/01/2016
Director TitleAgeSince
Director/Board Member 68 01/01/2016
Chairman 73 07/05/2020
Director/Board Member 40 01/01/2023
Date Insider Type Main position Quantity % Market Cap. Importance
1/7/26 Buy

Chairman

31,000 38.8588%
1/7/26 Buy

Chief Technology Officer

4,016,742 -
1/7/26 Buy

Chief Executive Officer

183,858 -
Change 5-day change 1-year change 3-year change Capi.($)
+2.26%-3.63%-18.44%-71.16% 29.07M
+1.15%+0.63%+56.30%+130.57% 1,140B
+0.45%+2.93%+40.29%+83.36% 641B
-0.11%-0.90%+25.64%+106.21% 507B
-0.15%+1.59%+48.13%+66.60% 383B
+0.25%-5.05%+60.01%+36.95% 347B
+1.68%+2.74%+25.98%+55.16% 293B
-0.16%+1.82%+2.41%+26.91% 266B
+0.01%+1.19%+52.55%+69.80% 240B
-0.98%+0.48%+30.54%+105.25% 197B
Average +0.41%+2.45%+32.34%+60.97% 401.38B
Weighted average by Cap. +0.43%+2.98%+42.14%+88.50%

Financials

2026 *2027 *
Net sales 101M 10.17M 9.09M 8.41M 7.61M 14.25M 967M 14.48M 40.03M 506M 38.15M 37.34M 1.6B 143M 14.38M 12.86M 11.9M 10.77M 20.17M 1.37B 20.5M 56.64M 716M 53.99M 52.83M 2.27B
Net income -36.1M -3.63M -3.24M -3M -2.72M -5.08M -345M -5.17M -14.28M -180M -13.61M -13.32M -571M 34.6M 3.48M 3.11M 2.88M 2.6M 4.87M 331M 4.95M 13.69M 173M 13.04M 12.77M 548M
Net Debt - -
Projected Income Statement - Annual - IRLAB Therapeutics AB
Logo IRLAB Therapeutics AB
IRLAB Therapeutics AB is a Sweden-based research and development company. It focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson’s disease. The Company possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The Company operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson’s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).
Employees
31
Date Price Change Volume
27/10/26 SEK 1.990 +2.26% 543,759
26/10/26 SEK 1.946 +0.93% 730,010
23/10/26 SEK 1.928 -2.72% 621,231
22/10/26 SEK 1.982 -4.48% 638,431
21/10/26 SEK 2.075 +0.48% 421,941

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - IRLAB Therapeutics AB
  1. Stock Market
  2. Stocks
  3. IRLAB A Stock